Ignite Creation Date:
2025-12-24 @ 3:57 PM
Ignite Modification Date:
2026-03-06 @ 6:09 AM
Study NCT ID:
NCT02868892
Status:
TERMINATED
Last Update Posted:
2018-11-02
First Post:
2016-05-02
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of Pemetrexed in Recurrent Cervical Adenocarcinomas
Sponsor:
Western Regional Medical Center
Organization:
Study Overview
Official Title:
A Phase II Study of Pemetrexed in Recurrent Cervical Adenocarcinomas
Status:
TERMINATED
Status Verified Date:
2018-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
departure of PI from institution and poor population for study participation
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patients with advanced or recurrent adenocarcinoma or adenosquamous cell carcinoma of the cervix will receive Pemetrexed.
Detailed Description:
Patients will receive Pemetrexed 500 mg/m2 every three week.
On initiation of pemetrexed, on day one of first chemotherapy cycle, patients will begin taking folic acid at a dose of 350 to 600 mcg daily as well as receive an intramuscular injection of 1000 mcg of vitamin B12, with subsequent vitamin B12 injections given every 9 weeks while on study.
On initiation of pemetrexed, on day one of first chemotherapy cycle, patients will begin taking folic acid at a dose of 350 to 600 mcg daily as well as receive an intramuscular injection of 1000 mcg of vitamin B12, with subsequent vitamin B12 injections given every 9 weeks while on study.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: